Ovarian/JJ
Cancer/NN
Prognostic/JJ
Prediction/NN
Model/NN
Using/VBG
RNA/NN
Sequencing/NN
Data/NNS
./.
====================
Ovarian/JJ
cancer/NN
is/VBZ
one/CD
of/IN
the/DT
leading/VBG
causes/VBZ
of/IN
cancer-related/JJ
deaths/NNS
in/IN
gynecological/JJ
malignancies/NNS
./.
====================
Over/RB
70/CD
%/NN
of/IN
ovarian/JJ
cancer/NN
cases/NNS
are/VBP
high-grade/JJ
serous/JJ
ovarian/JJ
cancers/NNS
and/CC
have/VBP
high/JJ
death/NN
rates/NNS
due/JJ
to/TO
their/PRP$
resistance/NN
to/TO
chemotherapy/NN
./.
====================
Despite/IN
advances/NNS
in/IN
surgical/JJ
and/CC
pharmaceutical/JJ
therapies/NNS
,/,
overall/JJ
survival/NN
rates/NNS
are/VBP
not/RB
good/JJ
,/,
and/CC
making/VBG
an/DT
accurate/JJ
prediction/NN
of/IN
the/DT
prognosis/NN
is/VBZ
not/RB
easy/RB
because/IN
of/IN
the/DT
highly/RB
heterogeneous/JJ
nature/NN
of/IN
ovarian/JJ
cancer/NN
./.
====================
To/TO
improve/VB
the/DT
patient/NN
’/CD
s/NNS
prognosis/NN
through/IN
proper/JJ
treatment/NN
,/,
we/PRP
present/VBP
a/DT
prognostic/JJ
prediction/NN
model/NN
by/IN
integrating/VBG
high-dimensional/JJ
RNA/NN
sequencing/NN
data/NNS
with/IN
their/PRP$
clinical/JJ
data/NNS
through/IN
the/DT
following/VBG
steps/NNS
:/:
gene/NN
filtration/NN
,/,
pre-screening/VBG
,/,
gene/NN
marker/NN
selection/NN
,/,
integrated/VBN
study/NN
of/IN
selected/VBN
gene/NN
markers/NNS
and/CC
prediction/NN
model/NN
building/VBG
./.
====================
These/DT
steps/NNS
of/IN
the/DT
prognostic/JJ
prediction/NN
model/NN
can/MD
be/VB
applied/VBN
to/TO
other/JJ
types/NNS
of/IN
cancer/NN
besides/VBZ
ovarian/JJ
cancer/NN
./.
====================
The/DT
genetic/JJ
background/NN
of/IN
patients/NNS
with/IN
complex/NN
diseases/NNS
,/,
such/JJ
as/IN
cancer/NN
,/,
has/VBZ
been/VBN
continually/RB
studied/VBN
./.
====================
Traditional/JJ
attempts/NNS
mainly/RB
focus/NN
on/IN
finding/NN
unique/JJ
differentially/RB
expressed/VBN
genes/NNS
(/(
DEGs/NNS
)/)
for/IN
diagnosis/NN
or/CC
survival/NN
times/NNS
using/VBG
microarray/NN
techniques/NNS
[/(
1/CD
,/,
2/CD
]/)
./.
====================
Genetic/JJ
markers/NNS
can/MD
be/VB
indicators/NNS
of/IN
the/DT
activity/NN
state/NN
of/IN
a/DT
pathway/NN
of/IN
therapy/NN
,/,
showing/VBG
their/PRP$
potential/JJ
as/IN
prognostic/JJ
predictors/NNS
for/IN
specific/JJ
treatments/NNS
./.
====================
Ovarian/JJ
cancer/NN
,/,
especially/RB
high-grade/JJ
serous/JJ
ovarian/JJ
cancer/NN
(/(
HGSC/NN
)/)
,/,
is/VBZ
one/CD
of/IN
the/DT
most/JJS
lethal/JJ
gynecological/JJ
malignancies/NNS
in/IN
women/NNS
./.
====================
Vague/NN
symptoms/NNS
and/CC
a/DT
lack/NN
of/IN
robust/JJ
biomarkers/NNS
for/IN
detection/NN
are/VBP
the/DT
main/JJ
causes/VBZ
of/IN
difficulties/NNS
in/IN
making/VBG
an/DT
early/JJ
diagnosis/NN
./.
====================
Major/JJ
factors/NNS
associated/VBN
with/IN
the/DT
poor/JJ
prognosis/NN
and/CC
poor/JJ
management/NN
of/IN
ovarian/JJ
cancers/NNS
include/VBP
the/DT
late/JJ
discovery/NN
of/IN
the/DT
disease/NN
,/,
chemotherapy/NN
resistance/NN
,/,
and/CC
a/DT
lack/NN
of/IN
clinical/JJ
variables/NNS
that/DT
are/VBP
crucial/JJ
for/IN
accurate/JJ
prognostic/JJ
predictions/NNS
[/(
3/CD
]/)
./.
====================
Thus/RB
,/,
there/EX
is/VBZ
a/DT
need/JJ
to/TO
identify/VB
new/JJ
biomarkers/NNS
that/IN
can/MD
be/VB
used/VBN
to/TO
improve/VB
the/DT
treatment/NN
of/IN
ovarian/JJ
cancer/NN
patients/NNS
[/(
4/CD
]/)
./.
====================
Previous/JJ
studies/NNS
have/VBP
mainly/RB
focused/VBN
on/IN
identifying/VBG
novel/JJ
molecular/JJ
markers/NNS
or/CC
subtyping/VBG
through/IN
molecular/JJ
markers/NNS
of/IN
HGSC/NN
[/(
5,6/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
aim/VBP
to/TO
identify/VB
clinical/JJ
and/CC
genetic/JJ
markers/NNS
of/IN
the/DT
prognosis/NN
of/IN
HGSC/NN
./.
====================
Through/IN
analyzing/VBG
high-dimensional/JJ
genetic/JJ
information/NN
,/,
we/PRP
can/MD
gain/VB
a/DT
better/RBR
understanding/NN
of/IN
HGSC/NN
and/CC
its/PRP$
biological/JJ
mechanism/NN
./.
====================
For/IN
cancers/NNS
with/IN
a/DT
poor/JJ
prognosis/NN
,/,
genetic/JJ
information/NN
can/MD
be/VB
effective/JJ
in/IN
improving/VBG
the/DT
prognosis/NN
of/IN
patients/NNS
based/VBN
only/RB
on/IN
clinical/JJ
information/NN
[/(
3/CD
]/)
./.
====================
Next-generation/NN
sequencing/NN
(/(
NGS/NN
)/)
technology/NN
has/VBZ
made/VBN
it/PRP
possible/JJ
to/TO
generate/VB
mRNA/NN
expression/NN
data/NNS
for/IN
the/DT
tens/NNS
of/IN
thousands/NNS
of/IN
genes/NNS
from/IN
only/RB
a/DT
few/JJ
hundred/VBD
samples/NNS
[/(
7/CD
]/)
./.
====================
These/DT
RNA/NN
sequencing/NN
(/(
RNA-Seq/NN
)/)
data/NNS
have/VBP
the/DT
advantage/NN
of/IN
knowing/VBG
the/DT
sequence/NN
count/NN
directly/RB
,/,
without/IN
being/VBG
affected/VBN
by/IN
the/DT
background/NN
noise/RB
,/,
unlike/IN
microarray/NN
data/NNS
./.
====================
RNA-Seq/NN
data/NNS
also/RB
contain/VBP
more/RBR
genes/NNS
to/TO
discover/JJ
than/IN
microarray/NN
data/NNS
./.
====================
High-throughput/JJ
NGS-based/JJ
tumor/NN
genome/NN
profiling/VBG
has/VBZ
significantly/RB
advanced/JJ
our/PRP$
understanding/NN
of/IN
the/DT
molecular/JJ
variability/NN
exhibited/VBD
by/IN
tumors/NNS
./.
====================
However/RB
,/,
the/DT
nature/NN
of/IN
RNA-Seq/NN
data/NNS
,/,
consisting/VBG
of/IN
non-negative/JJ
count/NN
data/NNS
,/,
requires/VBZ
a/DT
new/JJ
predictive/JJ
model/NN
that/DT
differs/VBZ
from/IN
that/DT
of/IN
microarray/NN
data/NNS
./.
====================
For/IN
RNA-Seq/NN
data/NNS
,/,
it/PRP
is/VBZ
difficult/JJ
to/TO
apply/RB
a/DT
traditional/JJ
statistical/JJ
approach/NN
because/IN
of/IN
its/PRP$
relatively/RB
small/JJ
number/NN
of/IN
samples/NNS
compared/VBN
with/IN
the/DT
large/JJ
number/NN
of/IN
genes/NNS
./.
====================
Therefore/RB
,/,
we/PRP
present/VBP
a/DT
process/NN
for/IN
finding/NN
genes/NNS
that/WDT
play/VBP
important/JJ
roles/NNS
in/IN
the/DT
outcome/NN
and/CC
specific/JJ
procedures/NNS
for/IN
designing/VBG
and/CC
evaluating/VBG
a/DT
model/NN
,/,
based/VBN
on/IN
the/DT
characteristics/NNS
of/IN
RNA-Seq/NN
data/NNS
./.
====================
The/DT
purpose/NN
of/IN
this/DT
study/NN
is/VBZ
to/TO
find/VB
gene/NN
markers/NNS
that/WDT
can/MD
significantly/RB
affect/VB
the/DT
prognosis/NN
,/,
when/WRB
analyzing/VBG
RNA-Seq/NN
data/NNS
,/,
and/CC
to/TO
present/JJ
a/DT
protocol/JJ
that/DT
can/MD
improve/VB
the/DT
predictive/JJ
performance/NN
using/VBG
transcription/NN
data/NNS
by/IN
integrating/VBG
clinical/JJ
information/NN
./.
====================
Specifically/RB
,/,
we/PRP
present/VBP
a/DT
protocol/JJ
to/TO
build/JJ
a/DT
prediction/NN
model/NN
for/IN
the/DT
prognosis/NN
of/IN
HGSC/NN
,/,
including/VBG
(/(
1/CD
)/)
selection/NN
of/IN
markers/NNS
and/CC
clinical/JJ
variables/NNS
and/CC
(/(
2/CD
)/)
model/NN
construction/NN
and/CC
evaluation/NN
./.
====================
The/DT
data/NNS
used/VBN
in/IN
this/DT
study/NN
were/VBD
clinical/JJ
information/NN
and/CC
RNA-Seq/NN
data/NNS
from/IN
The/DT
Cancer/NN
Genome/NN
Atlas/NNS
(/(
TCGA/NN
)/)
Genomic/JJ
Data/NNS
Commons/NNS
(/(
GDC/NN
)/)
portal/JJ
(/(
https/NNS
:/:
//portal.gdc.cancer.gov/LS
)/)
./.
====================
The/DT
National/JJ
Institutes/NNS
of/IN
Health/NN
(/(
NIH/NN
)/)
’/CD
s/NNS
TCGA/NN
webpage/NN
provides/VBZ
clinical/JJ
information/NN
,/,
biomedical/JJ
slide/JJ
images/VBZ
,/,
molecular/JJ
information/NN
,/,
CpG/NN
methylation/NN
information/NN
,/,
DNA/NN
copy/NN
number/NN
,/,
mRNA/NN
expression/NN
,/,
and/CC
miRNA/JJ
expression/NN
./.
====================
RNA-Seq/NN
data/NNS
were/VBD
used/VBN
,/,
because/IN
large/JJ
amounts/NNS
of/IN
gene/NN
expression/NN
could/MD
be/VB
explored/VBN
collectively/RB
from/IN
samples/NNS
in/IN
the/DT
study/NN
./.
====================
We/PRP
downloaded/VBD
genomic/JJ
alteration/NN
data/NNS
and/CC
expression/NN
data/NNS
in/IN
patients/NNS
with/IN
high-grade/JJ
serous/JJ
ovarian/JJ
cancer/NN
and/CC
the/DT
corresponding/JJ
clinicopathological/JJ
profiles/NNS
from/IN
the/DT
Genomic/JJ
Data/NNS
Commons/NNS
(/(
https/NNS
:/:
//portal.gdc.cancer.gov/LS
)/)
,/,
Firebrowse/RB
(/(
http/NN
:/:
//firebrowse.org/JJ
)/)
,/,
and/CC
cBioPortal/JJ
for/IN
Cancer/NN
Genomics/NNS
(/(
http/NN
:/:
//www.cbioportal.org/JJ
)/)
web/NN
portals/NNS
./.
====================
This/DT
study/NN
complied/VBD
with/IN
TCGA/NN
publication/NN
guidelines/NNS
and/CC
policies/NNS
(/(
http/NN
:/:
//cancergenome.nih.gov/publications/publicationguidelines/NNS
)/)
./.
====================
The/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
ruled/JJ
that/DT
no/DT
formal/JJ
ethical/JJ
approval/JJ
was/VBD
required/VBN
in/IN
this/DT
study.Survival/JJ
time/NN
refers/VBZ
to/TO
the/DT
period/NN
from/IN
the/DT
diagnosis/NN
of/IN
HGSC/NN
in/IN
patients/NNS
to/TO
death/NN
./.
====================
Clinical/JJ
variables/NNS
were/VBD
selected/VBN
,/,
based/VBN
on/IN
their/PRP$
influence/NN
on/IN
the/DT
outcome/NN
./.
====================
Among/IN
365/CD
HGSC/NN
cases/NNS
,/,
the/DT
median/JJ
survival/NN
time/NN
for/IN
the/DT
samples/NNS
was/VBD
43.9/CD
months/NNS
,/,
and/CC
the/DT
censoring/JJ
proportion/NN
of/IN
the/DT
data/NNS
was/VBD
55/CD
%/NN
./.
====================
Pre-processing/VBG
====================
HGSC/NN
patient/NN
data/NNS
collected/VBD
from/IN
the/DT
GDC/NN
portal/JJ
can/MD
be/VB
separated/VBN
into/IN
two/CD
categories/NNS
./.
====================
Since/IN
RNA-seq/JJ
data/NNS
from/IN
the/DT
GDC/NN
portal/JJ
consist/VBP
of/IN
raw/JJ
count/NN
data/NNS
,/,
normalization/NN
was/VBD
required/VBN
to/TO
control/VB
for/IN
the/DT
sample/NN
bias/NNS
and/CC
gene/NN
length/NN
bias/NNS
./.
====================
Two/CD
common/JJ
normalization/NN
methods/NNS
were/VBD
applied/VBN
./.
====================
The/DT
first/JJ
method/NN
is/VBZ
called/VBN
relative/JJ
long/JJ
expression/NN
(/(
RLE/NN
)/)
normalization/NN
,/,
implemented/VBD
in/IN
the/DT
R/NN
package/NN
“/CD
Deseq2/IN
”/CD
[/(
8/CD
]/)
,/,
which/WDT
is/VBZ
also/RB
implemented/VBD
in/IN
the/DT
R/NN
package/NN
“/CD
edgeR/NN
”/CD
[/(
9/CD
]/)
./.
====================
The/DT
RLE/NN
method/NN
utilizes/VBZ
the/DT
geometric/JJ
mean/NN
of/IN
the/DT
read/JJ
count/NN
,/,
whereas/IN
the/DT
TMM/NN
method/NN
estimates/NNS
normalizing/VBG
factors/NNS
after/IN
extreme/JJ
expressions/NNS
are/VBP
removed/VBN
to/TO
get/VB
more/RBR
a/DT
robust/JJ
estimation/NN
./.
====================
A/DT
simple/JJ
simulation/NN
study/NN
for/IN
DEGs/NNS
has/VBZ
been/VBN
performed/VBN
for/IN
comparison/NN
[/(
10/CD
]/)
./.
====================
Both/DT
methods/NNS
were/VBD
used/VBN
to/TO
give/VB
more/RBR
specific/JJ
comparison/NN
results/NNS
in/IN
the/DT
model/NN
building/VBG
./.
====================
Since/IN
the/DT
clinical/JJ
data/NNS
had/VBD
many/JJ
missing/JJ
values/NNS
,/,
we/PRP
imputed/VBD
missing/VBG
clinical/JJ
variables/NNS
with/IN
the/DT
R/NN
package/NN
“/CD
mice/NNS
,/,
”/NNP
which/WDT
performs/VBZ
chained/VBN
equations/NNS
to/TO
find/VB
estimates/NNS
for/IN
missing/VBG
values/NNS
using/VBG
Gipps/NNS
sampling/JJ
[/(
11/CD
]/)
./.
====================
There/EX
were/VBD
no/DT
tendencies/NNS
in/IN
the/DT
missing/JJ
values/NNS
;/:
so/RB
,/,
the/DT
missing-at-random/JJ
assumption/NN
was/VBD
applied/VBN
[/(
11/CD
]/)
./.
====================
After/IN
imputation/NN
,/,
significant/JJ
clinical/JJ
variables/NNS
were/VBD
chosen/NN
using/VBG
a/DT
Cox/NN
regression/NN
model/NN
via/IN
stepwise/JJ
selection/NN
methods/NNS
./.
====================
Clinical/JJ
data/NNS
and/CC
RNA-Seq/NN
data/NNS
were/VBD
integrated/VBN
and/CC
divided/VBN
into/IN
training/VBG
and/CC
test/NN
sets/NNS
./.
====================
To/TO
avoid/VB
unwanted/JJ
effects/NNS
of/IN
censoring/JJ
,/,
balanced/JJ
sampling/JJ
in/IN
terms/NNS
of/IN
censoring/JJ
status/NN
was/VBD
used/VBN
to/TO
make/VB
the/DT
training/VBG
and/CC
test/VB
sets/NNS
have/VBP
the/DT
same/JJ
censoring/JJ
rate/NN
./.
====================
Analysis/NN
plan/NN
====================
In/IN
this/DT
study/NN
,/,
we/PRP
considered/VBD
a/DT
prediction/NN
model/NN
and/CC
process/NN
in/IN
terms/NNS
of/IN
performance/NN
and/CC
interpretability/NN
./.
====================
The/DT
main/JJ
steps/NNS
of/IN
our/PRP$
analysis/NN
were/VBD
as/IN
follows/VBZ
:/:
(/(
1/CD
)/)
gene/NN
filtration/NN
,/,
(/(
2/CD
)/)
pre-screening/VBG
,/,
(/(
3/CD
)/)
gene/NN
marker/NN
selection/NN
,/,
and/CC
(/(
4/CD
)/)
integrated/VBD
study/NN
of/IN
selected/VBN
gene/NN
markers/NNS
and/CC
the/DT
final/JJ
prediction/NN
model/NN
./.
====================
Gene/NN
filtration/NN
====================
Gene/NN
filtration/NN
for/IN
low/JJ
expression/NN
is/VBZ
important/JJ
because/IN
it/PRP
can/MD
reduce/VB
false/VBP
positives/VBZ
[/(
12/CD
]/)
./.
====================
Sampling/VBG
noise/RB
that/DT
is/VBZ
added/VBN
during/IN
the/DT
sequencing/NN
process/NN
can/MD
also/RB
be/VB
removed/VBN
by/IN
gene/NN
filtration/NN
./.
====================
In/IN
this/DT
study/NN
,/,
a/DT
20/CD
%/NN
zero/CD
proportion/NN
threshold/NN
was/VBD
selected/VBN
,/,
as/IN
this/DT
value/NN
is/VBZ
commonly/RB
chosen/NN
in/IN
previous/JJ
studies/NNS
[/(
13/CD
]/)
./.
====================
Gene/NN
filtration/NN
was/VBD
performed/VBN
only/RB
on/IN
the/DT
training/VBG
set/NN
./.
====================
Pre-screening/VBG
====================
Pre-screening/VBG
of/IN
gene/NN
markers/NNS
was/VBD
used/VBN
after/IN
gene/NN
filtration/NN
./.
====================
This/DT
process/NN
is/VBZ
necessary/JJ
for/IN
actual/JJ
computation/NN
and/CC
controlling/VBG
false/NN
positives/VBZ
./.
====================
Unsupervised/JJ
filtering/VBG
using/VBG
median/JJ
absolute/JJ
deviation/NN
(/(
MAD/NN
)/)
was/VBD
used/VBN
./.
====================
MAD/NN
is/VBZ
widely/RB
used/VBN
in/IN
microarray/NN
data/NNS
and/CC
single-cell/JJ
RNA-Seq/NN
data/NNS
as/IN
a/DT
pre-screening/JJ
method/NN
./.
====================
This/DT
measure/NN
can/MD
be/VB
used/VBN
to/TO
select/VB
more/RBR
variable/JJ
genes/NNS
./.
====================
Compared/VBN
with/IN
standard/JJ
deviation/NN
,/,
MAD/NN
is/VBZ
a/DT
more/RBR
robust/JJ
measure/NN
[/(
14/CD
]/)
./.
====================
Since/IN
the/DT
raw/NN
count/NN
data/NNS
consist/VBP
of/IN
sparse/JJ
and/CC
non-negative/JJ
numbers/NNS
,/,
MAD/NN
was/VBD
used/VBN
to/TO
represent/VB
variability/NN
./.
====================
The/DT
genes/NNS
with/IN
MAD/NN
were/VBD
selected/VBN
for/IN
model/NN
building/VBG
./.
====================
Another/DT
supervised/VBD
pre-screening/VBG
method/NN
was/VBD
used/VBN
,/,
based/VBN
on/IN
univariate/JJ
Cox/NN
regression/NN
with/IN
adjustment/JJ
of/IN
clinical/JJ
variables/NNS
./.
====================
This/DT
Cox/NN
regression/NN
procedure/NN
was/VBD
performed/VBN
only/RB
for/IN
the/DT
training/VBG
set/NN
to/TO
avoid/VB
overfitting/VBG
./.
====================
Next/RB
,/,
genes/NNS
were/VBD
selected/VBN
,/,
based/VBN
on/IN
individual/JJ
p-values/NNS
./.
====================
Both/DT
methods/NNS
were/VBD
jointly/RB
applied/VBN
to/TO
select/VB
candidate/NN
gene/NN
markers/NNS
./.
====================
Gene/NN
selection/NN
====================
Although/IN
the/DT
pre-screening/VBG
process/NN
greatly/RB
reduced/VBD
the/DT
number/NN
of/IN
genes/NNS
,/,
there/EX
remained/VBD
the/DT
problem/NN
of/IN
an/DT
ill-posed/JJ
model/NN
,/,
since/IN
the/DT
sample/JJ
size/NN
was/VBD
very/RB
small/JJ
compared/VBN
to/TO
the/DT
number/NN
of/IN
features/NNS
./.
====================
Therefore/RB
,/,
sequential/JJ
variable/JJ
selection/NN
using/VBG
a/DT
multiple/JJ
Cox/NN
regression/NN
model/NN
was/VBD
not/RB
applicable/JJ
./.
====================
To/TO
solve/VB
such/JJ
a/DT
problem/NN
,/,
as/IN
presented/VBN
below/IN
,/,
multiple/JJ
Cox/NN
regression/NN
using/VBG
penalized/VBN
partial/JJ
likelihood/JJ
was/VBD
used/VBN
for/IN
variable/JJ
selection/NN
and/CC
shrinkage/NN
estimation/NN
./.
====================
β/RB
^/CD
=/JJ
argmin/NN
β/RB
1/CD
n/NN
[/(
Σ/NNP
s/NNS
=/JJ
1/CD
S/NN
-/:
X/NN
i/LS
s/NNS
t/NN
+/JJ
log/NN
{/CD
Σ/NNP
i/LS
∈/CD
R/NN
s/NNS
exp/NN
(/(
X/NN
i/LS
s/NNS
t/NN
β/JJ
)/)
}/CD
]/)
+/CC
P/NN
α/RB
,/,
λ/RB
(/(
β/LS
)/)
,/,
====================
where/WRB
Pα/JJ
,/,
λ/RB
(/(
β/LS
)/)
=Σc=1Cλ/JJ
(/(
δ∣βc∣+0.5/CD
(/(
1-δ/CD
)/)
βc2/NN
)/)
+Σg=1Gλ/CC
(/(
δ∣βg∣+0.5/CD
(/(
1-δ/CD
)/)
βg2/NN
)/)
is/VBZ
the/DT
penalty/NN
function/NN
./.
====================
Note/RB
that/DT
C/NN
and/CC
G/NN
are/VBP
the/DT
indicator/NN
sets/NNS
of/IN
clinical/JJ
and/CC
genetic/JJ
variables/NNS
,/,
respectively/RB
./.
====================
Modified/VBN
partial/JJ
likelihood/JJ
was/VBD
also/RB
used/VBN
to/TO
select/VB
clinical/JJ
variables/NNS
more/RBR
favorably/RB
,/,
since/IN
some/DT
clinical/JJ
variables/NNS
have/VBP
already/RB
been/VBN
reported/VBN
to/TO
be/VB
significant/JJ
./.
====================
P/NN
γ/RB
,/,
α/RB
,/,
λ/RB
(/(
β/RB
)/)
=/JJ
Σ/CD
c/NN
=/JJ
1/CD
C/NN
λ/RB
γ/RB
(/(
δ/RB
∣/CD
β/RB
c/NN
∣/NN
+/CC
0.5/CD
(/(
1/LS
-/:
δ/DT
)/)
β/RB
c/NN
2/CD
)/)
+/CC
Σ/NNP
g/NN
=/JJ
1/CD
∣/NN
G/NN
˜/NNP
∣/CD
λ/RB
(/(
δ/RB
∣/CD
β/RB
g/NN
∣/CD
+/CC
0.5/CD
(/(
1/LS
-/:
δ/DT
)/)
β/RB
g/NN
2/CD
)/)
====================
Thus/RB
,/,
the/DT
penalty/NN
factor/NN
γ/NN
is/VBZ
used/VBN
to/TO
reduce/VB
the/DT
penalty/NN
of/IN
clinical/JJ
variables/NNS
./.
====================
The/DT
partial/JJ
likelihood/JJ
estimation/NN
process/NN
explained/VBN
above/IN
is/VBZ
implemented/VBN
in/IN
the/DT
R/NN
package/NN
“/CD
glmnet/NN
,/,
”/CD
also/RB
known/VBN
as/IN
“/CD
coxnet/NN
”/CD
[/(
15/CD
]/)
./.
====================
Prediction/NN
model/NN
building/VBG
and/CC
detailed/JJ
study/NN
of/IN
selected/VBN
genes/NNS
====================
Along/IN
with/IN
selected/VBN
genetic/JJ
markers/NNS
and/CC
clinical/JJ
variables/NNS
we/PRP
fitted/VBD
a/DT
multiple/JJ
Cox/NN
regression/NN
model/NN
./.
====================
For/IN
further/RBR
integrated/VBN
study/NN
of/IN
the/DT
selected/VBN
gene/NN
markers/NNS
,/,
we/PRP
grouped/VBD
patients/NNS
into/IN
two/CD
groups/NNS
in/IN
terms/NNS
of/IN
fitted/JJ
hazard/JJ
ratios/NNS
as/IN
high-/JJ
and/CC
low-risk/JJ
groups/NNS
./.
====================
Then/RB
,/,
log/NN
rank/VBP
test/NN
was/VBD
performed/VBN
to/TO
test/VB
for/IN
homogeneity/NN
of/IN
survival/NN
rates/NNS
between/IN
the/DT
two/CD
groups/NNS
./.
====================
Also/RB
,/,
a/DT
functional/JJ
study/NN
for/IN
the/DT
selected/VBN
gene/NN
markers/NNS
using/VBG
a/DT
pathway/NN
database/NN
was/VBD
provided/VBN
for/IN
biological/JJ
understanding/NN
[/(
16/CD
]/)
./.
====================
To/TO
build/JJ
and/CC
validate/NN
the/DT
prediction/NN
models/NNS
,/,
the/DT
whole/JJ
dataset/NN
was/VBD
divided/VBN
into/IN
training/VBG
and/CC
test/VB
datasets/NNS
at/IN
a/DT
2:1/NN
ratio/NN
./.
====================
Clinical/JJ
results/NNS
====================
Descriptive/JJ
statistics/NNS
of/IN
the/DT
clinical/JJ
information/NN
are/VBP
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
First/RB
,/,
all/DT
categorical/JJ
variables/NNS
were/VBD
represented/VBN
by/IN
dummy/JJ
variables/NNS
./.
====================
Note/RB
that/DT
each/DT
variable/JJ
has/VBZ
less/RBR
than/IN
30/CD
%/NN
of/IN
observations/NNS
missing/VBG
./.
====================
When/WRB
we/PRP
put/VBP
all/DT
variables/NNS
together/RB
,/,
however/RB
,/,
they/PRP
made/VBD
up/IN
more/RBR
than/IN
40.55/CD
%/NN
of/IN
observations/NNS
with/IN
at/IN
least/JJS
one/CD
variable/JJ
missing/VBG
./.
====================
To/TO
include/VB
cases/NNS
with/IN
missing/JJ
variables/NNS
,/,
imputation/NN
was/VBD
performed/VBN
using/VBG
the/DT
“/NN
mice/NNS
”/CD
package/NN
./.
====================
Variable/JJ
selection/NN
of/IN
clinical/JJ
variables/NNS
was/VBD
performed/VBN
for/IN
Cox/NN
regression/NN
by/IN
using/VBG
stepwise/JJ
selection/NN
procedures/NNS
./.
====================
The/DT
results/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
2/CD
./.
====================
A/DT
total/JJ
of/IN
6/CD
clinical/JJ
variables/NNS
were/VBD
chosen/NN
out/RP
of/IN
26/CD
variables/NNS
./.
====================
Among/IN
the/DT
6/CD
variables/NNS
,/,
platinum/NN
status/NN
and/CC
primal/JJ
therapy/NN
outcome/NN
were/VBD
significant/JJ
for/IN
prognosis/NN
at/IN
a/DT
5/CD
%/NN
significance/NN
level/NN
./.
====================
Gene/NN
marker/NN
selection/NN
====================
After/IN
applying/VBG
a/DT
20/CD
%/NN
zero/CD
proportion/NN
threshold/NN
for/IN
filtration/NN
,/,
a/DT
total/JJ
of/IN
42,747/CD
genes/NNS
were/VBD
selected/VBN
./.
====================
For/IN
ease/NN
of/IN
interpretation/NN
,/,
only/RB
protein-coding/VBG
genes/NNS
and/CC
microRNA/NN
genes/NNS
,/,
which/WDT
numbered/VBD
up/IN
to/TO
18,415/CD
genes/NNS
,/,
were/VBD
used/VBN
./.
====================
We/PRP
performed/VBD
two/CD
pre-screening/VBG
processes/NNS
./.
====================
The/DT
first/JJ
one/CD
used/VBN
MAD/NN
./.
====================
Genes/NNS
with/IN
MAD/NN
under/IN
the/DT
10/CD
%/NN
quantile/JJ
were/VBD
filtered/VBN
out/RP
to/TO
control/VB
false/VBP
positives/VBZ
./.
====================
The/DT
second/JJ
filtering/NN
was/VBD
performed/VBN
using/VBG
p-values/NNS
of/IN
the/DT
gene/NN
markers/NNS
./.
====================
After/IN
that/DT
,/,
genes/NNS
with/IN
p-values/NNS
larger/JJR
than/IN
0.3/CD
were/VBD
removed/VBN
./.
====================
After/IN
the/DT
prescreening/VBG
,/,
6,161/CD
genes/NNS
remained/VBD
./.
====================
We/PRP
then/RB
fit/VBP
the/DT
modified/VBN
penalized/VBD
Cox/NN
regression/NN
model/NN
as/IN
explained/VBN
in/IN
the/DT
Methods/NNS
section/NN
./.
====================
Among/IN
the/DT
many/JJ
values/NNS
,/,
0.2/CD
was/VBD
chosen/NN
as/IN
the/DT
gamma/NN
parameter/NN
to/TO
be/VB
effective/JJ
for/IN
both/DT
marker/NN
selection/NN
and/CC
prediction/NN
in/IN
this/DT
study/NN
./.
====================
Finally/RB
,/,
three/CD
genes—REN/JJ
,/,
LEFTY1/NN
,/,
and/CC
AP1S2—were/JJ
selected/VBN
,/,
along/IN
with/IN
6/CD
clinical/JJ
variables/NNS
./.
====================
These/DT
selected/VBN
markers/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
3/CD
./.
====================
Integrated/JJ
study/NN
of/IN
selected/VBN
gene/NN
markers/NNS
====================
Along/IN
with/IN
the/DT
selected/VBN
genetic/JJ
markers/NNS
and/CC
clinical/JJ
variables/NNS
,/,
we/PRP
fitted/VBD
a/DT
multiple/JJ
Cox/NN
regression/NN
model/NN
./.
====================
The/DT
genetic/JJ
markers/NNS
chosen/NN
for/IN
the/DT
final/JJ
model/NN
were/VBD
REN/NN
,/,
LEFTY1/NN
,/,
and/CC
AP1S2/NN
./.
====================
From/IN
the/DT
Kyoto/NN
Encyclopedia/NN
of/IN
Genes/NNS
and/CC
Genomes/NNS
(/(
KEGG/NN
)/)
pathway/NN
database/NN
[/(
16/CD
]/)
,/,
we/PRP
found/VBD
out/IN
that/DT
these/DT
genes/NNS
belong/IN
to/TO
the/DT
following/VBG
pathways/NNS
,/,
respectively/RB
:/:
KEGG/NN
RENIN/NN
ANGIOTENSIN/NN
SYSTEM/NN
,/,
KEGG/NN
TGF/NN
BETA/NN
SIGNALING/NN
PATHWAY/NN
,/,
and/CC
KEGG/NN
LYSOSOME/NN
./.
====================
The/DT
false/JJ
discovery/NN
rate/NN
q-values/NNS
from/IN
the/DT
univariate/JJ
Cox/NN
regression/NN
with/IN
a/DT
single/JJ
gene/NN
were/VBD
0.693/CD
,/,
0.687/CD
,/,
and/CC
0.138/CD
,/,
respectively/RB
./.
====================
These/DT
q-values/NNS
mean/NN
that/DT
those/DT
genetic/JJ
markers/NNS
can/MD
not/RB
be/VB
selected/VBN
through/IN
the/DT
false/NN
discovery/NN
rate/NN
procedure/NN
with/IN
a/DT
level/NN
of/IN
0.1/CD
via/IN
univariate/JJ
Cox/NN
regression/NN
./.
====================
For/IN
further/RBR
integrated/VBN
study/NN
of/IN
the/DT
selected/VBN
gene/NN
markers/NNS
,/,
we/PRP
grouped/VBD
patients/NNS
into/IN
two/CD
groups—high-/JJ
and/CC
low-risk—/JJ
using/VBG
the/DT
fitted/JJ
hazard/JJ
ratios/NNS
./.
====================
As/IN
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
,/,
the/DT
two/CD
groups/NNS
were/VBD
well/RB
separated/VBN
,/,
with/IN
a/DT
log-rank/NN
test/NN
p-value/NN
of/IN
8.02×10−6/CD
./.
====================
We/PRP
could/MD
see/VB
that/DT
our/PRP$
model/NN
predicts/VBZ
the/DT
prognosis/NN
of/IN
patients/NNS
quite/RB
well/RB
./.
====================
The/DT
three/CD
selected/VBN
genes/NNS
have/VBP
been/VBN
reported/VBN
to/TO
have/VB
an/DT
association/NN
with/IN
ovarian/JJ
cancer/NN
in/IN
previous/JJ
studies/NNS
./.
====================
The/DT
renin-angiotensin/JJ
system/NN
works/VBZ
as/IN
an/DT
angiogenic/JJ
factor/NN
through/IN
type/NN
1/CD
angiotensin/NN
receptors/NNS
./.
====================
These/DT
angiogenic/JJ
factors/NNS
have/VBP
a/DT
correlation/NN
with/IN
ovarian/JJ
cancer/NN
patient/NN
survival/NN
[/(
17/CD
]/)
./.
====================
Lefty1/NN
is/VBZ
an/DT
activator/NN
of/IN
the/DT
TCEA3/NN
gene/NN
,/,
the/DT
expression/NN
of/IN
which/WDT
is/VBZ
related/JJ
to/TO
cell/NN
death/NN
in/IN
ovarian/JJ
cancer/NN
[/(
18/CD
]/)
./.
====================
Lastly/RB
,/,
AP1S2/NN
has/VBZ
been/VBN
reported/VBN
as/IN
a/DT
prognostic/JJ
marker/NN
of/IN
ovarian/JJ
cancer/NN
,/,
and/CC
its/PRP$
expression/NN
level/NN
is/VBZ
differentially/RB
changed/VBN
in/IN
drug-resistant/JJ
cell/NN
lines/NNS
[/(
19/CD
,/,
20/CD
]/)
./.
====================
Prediction/NN
model/NN
results/VBZ
====================
Two/CD
measures/NNS
of/IN
assessment/NN
were/VBD
considered/VBN
./.
====================
One/CD
was/VBD
Harrell/JJ
’/CD
s/NNS
concordance/NN
index/NN
,/,
and/CC
the/DT
other/JJ
was/VBD
the/DT
2-year/JJ
time-dependent/JJ
area/NN
under/IN
the/DT
receiver/NN
operating/VBG
characteristic/JJ
curve/JJ
(/(
AUC/NN
)/)
[/(
21/CD
,/,
22/CD
]/)
./.
====================
For/IN
purposes/NNS
of/IN
comparison/NN
,/,
we/PRP
considered/VBD
three/CD
models/NNS
:/:
a/DT
multiple/JJ
Cox/NN
model/NN
with/IN
only/RB
clinical/JJ
variables/NNS
(/(
M1/NN
)/)
,/,
penalized/VBD
Cox/NN
regression/NN
(/(
M2/NN
)/)
,/,
and/CC
our/PRP$
proposed/JJ
method/NN
(/(
M3/NN
)/)
./.
====================
Table/JJ
4/CD
shows/VBZ
the/DT
C-index/NN
and/CC
time-dependent/JJ
AUC/NN
of/IN
each/DT
model/NN
./.
====================
Among/IN
the/DT
three/CD
models/NNS
,/,
penalized/VBD
Cox/NN
regression/NN
M2/NN
showed/VBD
even/RB
worse/NN
results/NNS
than/IN
M1/NN
alone/RB
with/IN
the/DT
clinical/JJ
variables/NNS
,/,
whereas/IN
our/PRP$
method/NN
,/,
M3/NN
,/,
showed/VBD
the/DT
best/JJS
performance/RB
./.
====================
The/DT
time-dependent/JJ
receiver/NN
operating/VBG
characteristic/JJ
curves/NNS
for/IN
the/DT
training/VBG
sets/NNS
and/CC
test/NN
sets/NNS
are/VBP
shown/VBN
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
In/IN
most/JJS
of/IN
the/DT
range/NN
of/IN
Fig/NN
./.
====================
2/CD
,/,
the/DT
curve/JJ
of/IN
M3/NN
is/VBZ
higher/JJR
than/IN
the/DT
other/JJ
curves/NNS
on/IN
in/IN
the/DT
upper/JJ
left/NN
corner/NN
,/,
showing/VBG
better/RBR
performance/NN
with/IN
regard/NN
to/TO
prognostic/JJ
prediction/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
presented/VBD
the/DT
process/NN
of/IN
building/VBG
prediction/NN
models/NNS
,/,
based/VBN
on/IN
clinical/JJ
variables/NNS
and/CC
high-dimensional/JJ
RNA-Seq/NN
data/NNS
for/IN
HSGC/NN
patients/NNS
provided/VBD
by/IN
the/DT
TCGA/NN
GDC/NN
portal/JJ
./.
====================
The/DT
specific/JJ
steps/NNS
were/VBD
as/IN
follows/VBZ
:/:
gene/NN
filtration/NN
,/,
pre-screening/VBG
,/,
gene/NN
marker/NN
selection/NN
,/,
and/CC
integrated/VBN
study/NN
of/IN
selected/VBN
gene/NN
markers/NNS
with/IN
the/DT
final/JJ
prediction/NN
model/NN
./.
====================
To/TO
put/VB
more/RBR
emphasis/NN
on/IN
the/DT
clinical/JJ
variables/NNS
,/,
we/PRP
applied/VBD
modified/VBN
penalized/VBD
Cox/NN
regression/NN
./.
====================
We/PRP
first/RB
selected/VBN
clinical/JJ
variables/NNS
that/DT
had/VBD
major/JJ
impacts/VBZ
on/IN
the/DT
survival/NN
outcome/RB
of/IN
HGSC/NN
,/,
and/CC
then/RB
,/,
we/PRP
found/VBD
genes/NNS
using/VBG
these/DT
clinical/JJ
variables/NNS
with/IN
higher/JJR
weights/NNS
than/IN
genes/NNS
in/IN
the/DT
penalized/VBN
Cox/NN
regression/NN
./.
====================
As/IN
shown/VBN
in/IN
Table/JJ
5/CD
,/,
six/CD
clinical/JJ
variables/NNS
and/CC
three/CD
genes/NNS
were/VBD
chosen/NN
as/IN
the/DT
markers/NNS
for/IN
prognostic/JJ
prediction/NN
./.
====================
While/IN
these/DT
three/CD
genes/NNS
were/VBD
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
HGSC/NN
,/,
no/DT
significant/JJ
results/NNS
were/VBD
found/VBN
in/IN
the/DT
single-gene/JJ
analysis/NN
./.
====================
When/WRB
analyzing/VBG
data/NNS
,/,
a/DT
single/JJ
marker/NN
alone/RB
may/MD
not/RB
be/VB
sufficient/JJ
to/TO
explain/VB
the/DT
outcome/NN
./.
====================
For/IN
example/NN
,/,
the/DT
RENIN/NN
gene/NN
itself/PRP
can/MD
not/RB
distinguish/VB
survival/NN
patterns/NNS
of/IN
ovarian/JJ
cancer/NN
patients/NNS
well/RB
./.
====================
However/RB
,/,
a/DT
model/NN
that/DT
includes/VBZ
additional/JJ
gene/NN
markers/NNS
can/MD
contribute/VB
to/TO
improving/VBG
the/DT
predictability/NN
by/IN
further/JJ
explaining/VBG
the/DT
areas/NNS
that/DT
can/MD
not/RB
be/VB
explained/VBN
by/IN
clinical/JJ
variables/NNS
[/(
20/CD
]/)
./.
====================
Furthermore/RB
,/,
it/PRP
is/VBZ
important/JJ
to/TO
keep/VB
in/IN
mind/JJ
that/DT
the/DT
issue/NN
of/IN
false/JJ
positives/VBZ
can/MD
arise/VB
,/,
since/IN
the/DT
analysis/NN
is/VBZ
conducted/VBN
with/IN
a/DT
relatively/RB
small/JJ
number/NN
of/IN
samples/NNS
compared/VBN
to/TO
the/DT
number/NN
of/IN
genes/NNS
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
important/JJ
to/TO
determine/VB
which/WDT
genes/NNS
to/TO
use/VB
in/IN
the/DT
Cox/NN
model/NN
by/IN
considering/VBG
the/DT
appropriate/JJ
gene/NN
filtering/VBG
criteria/NNS
./.
====================
We/PRP
proposed/VBD
procedures/NNS
for/IN
building/VBG
prediction/NN
models/NNS
for/IN
predicting/VBG
survival/NN
outcomes/NNS
by/IN
integrating/VBG
RNA-Seq/NN
data/NNS
and/CC
clinical/JJ
information/NN
for/IN
HGSC/NN
./.
====================
The/DT
approach/NN
in/IN
this/DT
study/NN
is/VBZ
general/JJ
,/,
in/IN
the/DT
sense/NN
that/DT
it/PRP
may/MD
not/RB
be/VB
highly/RB
dependent/JJ
on/IN
the/DT
characteristics/NNS
of/IN
the/DT
cancer/NN
type/NN
or/CC
other/JJ
types/NNS
of/IN
biomarkers/NNS
./.
====================
Therefore/RB
,/,
this/DT
predictive/JJ
model/NN
development/NN
process/NN
could/MD
be/VB
easily/RB
applied/VBN
to/TO
other/JJ
types/NNS
of/IN
cancer/NN
./.
====================
In/IN
the/DT
future/JJ
,/,
we/PRP
hope/VBP
to/TO
apply/RB
our/PRP$
approach/NN
to/TO
other/JJ
types/NNS
of/IN
genomic/JJ
data/NNS
,/,
such/JJ
as/IN
DNA/NN
methylation/NN
and/CC
copy/NN
number/NN
alterations/NNS
./.
====================
In/IN
addition/NN
,/,
we/PRP
want/VBD
to/TO
build/JJ
our/PRP$
integrative/JJ
prediction/NN
model/NN
to/TO
predict/VB
survival/NN
times/NNS
more/RBR
accurately/RB
for/IN
other/JJ
cancer/NN
patients/NNS
./.
====================
Survival/NN
curve/NN
based/VBN
on/IN
predicted/VBN
values/NNS
(/(
3/CD
genetic/JJ
markers/NNS
with/IN
6-clinical-variable/JJ
adjustment/JJ
,/,
time/NN
unit/NN
is/VBZ
month/NN
)/)
./.
====================
Time-dependent/JJ
receiver/RB
operating/VBG
characteristic/JJ
(/(
ROC/NN
)/)
curves/VBZ
of/IN
the/DT
three/CD
models/NNS
for/IN
the/DT
test/NN
dataset/NN
./.
====================
Descriptive/JJ
statistics/NNS
for/IN
clinical/JJ
information/NN
====================
Variable/JJ
selection/NN
results/VBZ
for/IN
clinical/JJ
variables/NNS
====================
Selected/VBN
gene/NN
markers/NNS
using/VBG
modified/VBN
penalized/VBD
Cox/NN
regression/NN
====================
Comparison/NN
of/IN
prediction/NN
with/IN
3/CD
methods/NNS
:/:
M1/NN
,/,
M2/NN
,/,
and/CC
M3/NN
====================
Model/NN
coefficients/NNS
and/CC
inferences/VBZ
for/IN
proposed/JJ
model/NN
====================
